Can reduced dose radiotherapy delivered in standard fractionation improve the therapeutic index for stereotactic treatment of juxtapapillary choroidal melanoma?

Peter MacCallum Cancer Centre0 sites20 target enrollmentMay 20, 2014

Overview

No summary available.

Registry

who.int

Start Date

May 20, 2014

End Date

TBD

Last Updated

2 years ago

Study Type

Interventional

Sex

All

Sponsor

Peter MacCallum Cancer Centre

•1\. Primary choroidal melanoma (small and medium sized)
•\- A clinical diagnosis of CM made by a suitably trained ophthalmologist is mandatory
•\- Features that define CM and must be present are a choroidal mass that is pigmented or hypopigmented AND EITHER:
•a) Tumour height measured on beta ultrasound to be 2\.5mm or greater OR
•b) Documented growth of a lesion \<2\.5mm in height
•2\. Tumour height to 8mm or less
•3\. Tumour basal diameter 16mm or less
•4\. Visual acuity better than 6/60 ( or 0\.1\)
•5\. No evidence of metastatic disease on liver ultrasound
•6\. Age 70 or less

•1\. Tumour involving the iris or ciliary body
•2\. Cytopathologic diagnosis is not uveal melanoma
•3\. Previous treatment to the affected eye with radiation, laser or thermotherapy
•4\. Non\-malignant disease of the affected eye (that already has or could affect vision)
•5\. Known to have diabetes mellitus
•6\. Prior diagnosis of cancer that was:
•\- more than 5 years prior to current diagnosis with subsequent evidence of disease recurrence or clinical expectation of recurrence is greater than 10%
•\- within 5 years of current diagnosis with the exception of successfully treated basal cell or squamous cell skin carcinoma or carcinoma in situ of the cervix
•7\. Patients with clinical evidence of metastatic disease.
•8\. Women who are pregnant